Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Rehwald U, Engert A, Diehl V, Muller-Hermelink K, Rüdiger T, Driessen C, Morschhauser F, Staak J, Sieber M, Reiser M, Schulz H, German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-4.
Jan 15, 2003
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Jan 15, 2003
Blood 2003; 101:420-4
Rehwald Ute, Engert Andreas, Diehl Volker, Muller-Hermelink Konrad, Rüdiger Thomas, Driessen Christoph, Morschhauser Franck, Staak Jan Oliver, Sieber Markus, Reiser Marcel, Schulz Holger, German Hodgkin Lymphoma Study Group (GHSG)
more
